APOA1 and type 2 diabetes mellitus: Probably, the use of apoA-I protein, which has glucose-regulating function and affects the components of innate and adaptive immunity, together with MSCs that have similar immunomodulatory functions, has great potential for the development of regulatory cell-mediated approaches for the treatment of T2D and its complications.